97269 ⎘
Immunoglobulins specific features characterized by post-translational modification
Anti-CD79B antibodies and immunoconjugates and methods of use
#302Method for the serological diagnosis of rheumatoid arthritis
#303METHODS OF TREATING TRANSPLANT REJECTION USING A DOMAIN ANTIBODY DIRECTED AGAINST CD40
#304Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
#305Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
#306Human Antibodies that Bind Human TNF-Alpha and Methods of Preparing the Same
#307Immunoconjugates with an intracellularly-cleavable linkage
#308HUMANIZED, ANTI-N2 ANTIBODIES
#309Anti-CLL-1 antibodies and methods of use
#310ANTI B7-H3 ANTIBODY
#311Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
#312Antibody conjugates and methods of making the antibody conjugates
#313Bispecific antibody binding to human TLR2 and human TLR4
#314FUNCTIONALIZED POLYPEPTIDES
#315OPTIMIZED FC VARIANTS
#316Enzymatic conjugation of polypeptides
#317Methods of treatment with bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1
#318Targeting of innate immune response to tumor site
#319Anti-PACAP antibodies
#320Optimized Fc variants
#321Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
#322Manufacturing methods to control C-terminal lysine, galactose and sialic acid content in recombinant proteins
#323Activated formylglycine-generating enzymes and methods of producing and using the same
#324LIPOSOME ENCAPSULATED AFFINITY DRUG
#325Anti-EGFR activatable antibodies
#326Anti-human tie-2 antibody
#327Immunoconjugates with an intracellularly-cleavable linkage
#328Anti-human TSLP receptor antibody
#329Immobilized Single Domain Antigen-Binding Molecules
#330BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF
#331Antibody derivatives
#332Labeled ligands of anti-Mullerian hormone for diagnosis of endometriosis
#333DE-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
#334Compositions and methods for antibodies targeting BMP6
#335Amino acid derivatives
#336Human monoclonal antibodies to O8E
#337Methods for producing subtypes of humanized antibody against interleukin-6 receptor
#338Glycoengineered antibody drug conjugates
#339Cysteine engineered antibodies and conjugates
#340IgG4 Fc fragment comprising modified hinge region
#341PROCESS FOR MANUFACTURING CONJUGATES OF IMPROVED HOMOGENEITY
#342Immunoconjugates with an intracellularly-cleavable linkage
#343Composition with reduced immunogenicity
#344PYRROLOBENZODIAZEPINES AND ANTIBODY DISULFIDE CONJUGATES THEREOF
#345Methods and compositions for analyzing proteins
#346Method for increasing pyro-glutamic acid formation of a protein
#347Anti-human TSLP receptor antibody
#348Anti-CDH6 antibody drug conjugates
#349Methods to modulate lysine variant distribution
#350Protein screening methods
#351Conjugates of an anti-TNF-alpha antibody
#352Recombinant polypeptide production
#353T CELL RECEPTOR MIMIC RL9A
#354Compositions and methods for inducing apoptosis
#355Anti-FGFR2 antibodies and pharmaceutical compositions thereof
#356Fusion immunomodulatory proteins and methods for making same
#357RADIOLABELED ANTI-GLYPICAN-3 IMMUNOCONJUGATES FOR IMMUNO-PET IMAGING OF HEPATOCELLULAR CARCINOMA
#358Modified Fc molecules
#359Methods for Predicting and Preventing Metastasis in Triple Negative Breast Cancers
#360Method for refolding antibody, process for producing refolded antibody, refolded antibody, and uses thereof
#361Deglycosylation Reagents and Methods
#362Anti-HER2 glycoantibodies and uses thereof
#363Chemically modified targeting protein and use thereof
#364Anti-CD79B antibodies and immunoconjugates and methods of use
#365ANALYSIS OF DISULFIDE BONDS
#366Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
#367Cell lines
#368RECEPTOR BINDING CONJUGATES
#369Covalently linked antigen-antibody conjugates
#370Amino acid derivatives
#371Fc variants with increased affinity for FcyRIIc
#372Anti-transglutaminase 2 antibodies
#373Bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1
#374Modified FC polypeptides, FC conjugates, and methods of use thereof
#375Process for preparing purified drug conjugates
#376Secretory immunoglobulin complex
#377CYSTEINE ENGINEERED ANTI-TENB2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#378Compositions comprising antibodies targeting factor P
#379ANTIBODIES WITH DECREASED DEAMIDATION PROFILES
#380Methods for oxime conjugation to ketone-modified polypeptides
#381Anti-FGFR2 antibodies and methods of use thereof for treating cancer
#382Human control antibodies and uses therefor
#383Hyperglycosylated binding polypeptides
#384COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITOR
#385Methods and compositions for increasing arylsulfatase A activity in the CNS
#386JCV neutralizing antibodies
#387Human antibodies that bind human TNF-alpha and methods of preparing the same
#388OPTIMIZED Fc VARIANTS
#389Meditopes and meditope-binding antibodies and uses thereof
#390METHOD FOR THE PRODUCTION OF VARIABLE DOMAINS
#391METHODS AND COMPOSITIONS FOR INCREASING ENZYME ACTIVITY IN THE CNS
#392Optimized Fc variants
#393Enzymatic conjugation of antibodies
#394Method of treating and reducing the risk of acute myelogenous leukemia
#395ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
#396Methods of preventing and removing trisulfide bonds
#397Site-specific antibody-drug conjugation through glycoengineering
#398Human antibodies that bind human TNF-alpha and methods of preparing the same
#399Mutated anti-TNFα antibodies and methods of their use
#400Compositions and methods for augmenting permeability barriers
#401Modified proteins and peptides
#402Anti-CD79B antibodies and immunoconjugates and methods of use
#403A-beta binding polypeptides
#404Antibodies that bind factor P
#405Methods to modulate lysine variant distribution
#406Enzymatic conjugation of polypeptides
#407Methods and compositions for increasing arylsulfatase A activity in the CNS
#408Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
#409Nucleic acid molecules encoding A-beta binding polypeptides
#410BIOLOGICAL PRODUCTS
#411Meditopes and meditope-binding antibodies and uses thereof
#412PROCESS FOR MANUFACTURING CONJUGATES OF IMPROVED HOMOGENEITY
#413De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
#414Modified antibody compositions, methods of making and using thereof
#415Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof
#416Modified antibody compositions, methods of making and using thereof
#417Anti-CD79B antibodies and immunoconjugates and methods of use
#418Method for the production of variable domains
#419ANTAGONISTS, USES & METHODS FOR PARTIALLY INHIBITING TNFR1
#420Compositions for analyzing proteins
#421Immunoconjugates with an intracellularly-cleavable linkage
#422A-beta binding polypeptides
#423MODIFIED SINGLE DOMAIN ANTIGEN BINDING MOLECULES AND USES THEREOF
#424Modified Fc molecules
#425ANTI-TNFR1 POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS
#426Immunoconjugates with an intracellularly-cleavable linkage
#427Aldehyde tags, uses thereof in site-specific protein modification
#428Aldehyde tags, uses thereof in site-specific protein modification
#429Functionalized polypeptides
#430Protein screening methods
#431Biological products
#432Anti-CD79B antibodies and immunoconjugates and methods of use
#433ANTIBODIES WITH DECREASED DEAMIDATION PROFILES
#434Targeting of innate immune response to tumor site
#435Optimized Fc Variants
#436Process for preparing purified drug conjugates
#437De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
#438Subtypes of humanized antibody against interleuken-6 receptor
#439Anti-CD79B antibodies and immunoconjugates and methods of use
#440ANTIBODY FORMULATION
#441MODIFIED ANTIBODY COMPOSITIONS, METHODS OF MAKING AND USING THEREOF
#442Immunoconjugates with an intracellularly-cleavable linkage
#443Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
#444Biological products
#445Conjugates of an anti-TNF-α antibody
#446Optimized Fc Variants and methods for their generation
#447Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
#448Human monoclonal antibodies to O8E
#449Anti-CD79B antibodies and immunoconjugates and methods of use
#450Fc Variants Having Decreased Affinity for FcyRIIb
#451METHODS AND COMPOSITIONS FOR ANALYZING PROTEINS
#452Aldehyde tags, uses thereof in site-specific protein modification
#453Fc Variants with Increased Affinity for FcyRIIc
#454Fc variants with increased affinity for FcγRIIc
#455Fc Variants with Increased Affinity for FcyRIIC
#456Fc Variants with Increased Affinity for FcyRIIc
#457Modified Fc molecules
#458Biological products
#459Process for preparing purified drug conjugates
#460Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
#461Ultra-stable protein ionic liquids